<DOC>
	<DOCNO>NCT02569476</DOCNO>
	<brief_summary>This study evaluate safety preliminary efficacy BGB-3111 combination obinutuzumab subject B-cell lymphoid malignancy .</brief_summary>
	<brief_title>BGB 3111 Combination With Obinutuzumab Subjects With B-Cell Lymphoid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<criteria>Aged ≥18 year , able willing provide write informed consent comply study protocol . Laboratory parameter specify : Hematologic : Platelet count &gt; 40x10^9/L ( may posttransfusion ) ; absolute neutrophil count &gt; 1.0x10^9/L ( growth factor use allow bring pretreatment neutrophil &gt; 1.0x10^9 cells/L marrow infiltration involve ) . Hepatic : Total bilirubin &lt; 3 x upper limit normal ( ULN ) ; aspartate aminotransferase ( AST ) alanine transaminase ( ALT ) ≤3xULN . Renal : Creatinine clearance ≥50 mL/min ( estimate Cockcroft Gault equation measure nuclear medicine scan 24 hour urine collection ) ; subject require hemodialysis exclude . Anticipated survival least 6 month . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 . Female subject childbearing potential nonsterile male must agree practice least one follow method birth control partner ( ) throughout study ≥3 month discontinue BGB3111 ≥18 month follow obinutuzumab treatment , whichever longer : total abstinence sexual intercourse , double barrier contraception , intra uterine device ( IUD ) hormonal contraceptive initiate least 3 month prior first administration study drug . Male subject must donate sperm first study drug administration , 3 month BGB3111 discontinuation 18 month follow obinutuzumab treatment , whichever longer . Known central nervous system lymphoma leukemia . Known prolymphocytic leukemia history , currently suspect , Richter 's syndrome . Uncontrolled autoimmune hemolytic anemia idiopathic thrombocytopenia purpura . History significant cardiovascular disease . Severe debilitate pulmonary disease . History severe allergic anaphylactic reaction monoclonal antibody therapy . Prior BTK inhibitor treatment . Using medication strong cytochrome P450 ( CYP ) 3A inhibitor strong CYP3A inducer . Vaccination live vaccine within 28 day initiation treatment . Allogeneic stem cell transplantation within 6 month , active graft versus host disease ( GvHD ) require ongoing immunosuppression . Receipt follow treatment prior first administration BGB 3111 , corticosteroid give antineoplastic intent within 7 day , chemotherapy radiotherapy within 3 week , monoclonal antibody within 4 week . Participate investigational drug study within 28 day study entry , recover nonhematologic toxicity prior chemotherapy ≤ Grade 1 ( except alopecia ) . History active malignancy within 2 year study entry . Major surgery past 4 week . Active symptomatic fungal , bacterial and/or viral infection include evidence infection human immunodeficiency virus ( HIV ) , human T cell lymphotropic virus ( HTLV 1 ) seropositive status . Inability comply study procedure . Pregnant nursing woman . Any illness condition opinion investigator may affect safety treatment evaluation study 's endpoint .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>BGB-3111</keyword>
	<keyword>Obinutuzumab</keyword>
	<keyword>B-cell</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Therapeutic us</keyword>
</DOC>